The Combating Illicit Xylazine Act aims to tackle the rising misuse of xylazine, a substance increasingly linked to public health concerns and illicit drug use. By classifying xylazine as a Schedule III controlled substance, the legislation seeks to regulate its availability and use, thereby preventing abuse while still allowing for legitimate medical applications. The Act introduces several key provisions, including the formal classification of xylazine under the Controlled Substances Act, which was previously unregulated.